David Schenkein
General Partner at GV (Google Ventures)
Boston, Massachusetts
Writes $250K – $50M checks · typically $25M
About
David Schenkein is a physician-investor, founding Agios CEO who oversaw metabolism‑targeting AML drug approvals, now a general partner who remains a clinician and warns non-dilutive deals can be more dilutive.
David Schenkein @schenkein
so proud to be a GV team member with @brobbs https://t.co/XBYQEDsJEM
Jul 24, 2026 · ♥ 3
David Schenkein @schenkein
Congrats to the entire Parabilis team- making an impact on the lives of patients in need https://t.co/AQVdsg1FS7
Jun 11, 2026 · ♥ 7
David Schenkein @schenkein
Was an incredibly special time in my career and honored to be with such an amazing group of people dedicated to make an impact https://t.co/Ez60gl6gQq
May 18, 2026 · ♥ 18 · ⇄ 3
Invests in
AI & Machine LearningBiotechConsumerDigital HealthEnterprise SoftwareHealthtechMedical Devices
Deals · 2
Treeline BiosciencesBoard seat
via GV (Google Ventures) · filed Sep 2025 · $250M raise
Denali TherapeuticsBoard seat
via GV (Google Ventures) · filed Mar 2024 · $499.7M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at GV (Google Ventures)
Network12
Investors connected to David in public investor directories — a warm-intro map.